SAB Biotherapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SABS research report →
Range $10 – $13
Price Chart
About the company
SAB Biotherapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials.
- CEO
- Samuel J. Reich
- IPO
- 2021
- Employees
- 86
- HQ
- Miami Beach, FL, US
Get TickerSpark's AI analysis on SABS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $266.59M
- P/E
- 0.82
- PEG
- 0.00
- P/S
- 0.00
- P/B
- 1.09
- EV/EBITDA
- -27.84
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -6.74%
- ROIC
- -31.62%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $-3,081,586+11.2%
- Op Income
- $-48,953,363
- Net Income
- $13.27M+138.9%
- EPS
- $0.22+106.0%
- OCF Growth
- -30.6%
- FCF Growth
- -32.0%
- 52W High
- $5.15
- 52W Low
- $2.10
- 50D MA
- $3.58
- 200D MA
- $3.77
- Beta
- 0.58
- RSI (14)
- 29
- Avg Volume
- 493.19K
No earnings-call transcripts are available for SABS yet.
- Free Float
- 84.2%
- Shares Outstanding
- 90.99M
- Float Shares
- 76.63M
of shares held by institutions
81 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Caligan Partners LP | 7.97M | 0 |
| Vivo Capital, LLC | 7.30M | ▼ 4.12M |
| Perceptive Advisors LLC | 6.63M | ▲ 195.76K |
| Adage Capital Partners Gp, L.L.C. | 6.41M | ▲ 3.00M |
| Ra Capital Management, L.P. | 4.40M | 0 |
| Balyasny Asset Management L.P. | 3.76M | 0 |
| Blackrock, Inc. | 3.07M | ▲ 2.76M |
| Vanguard Capital Management LLC | 2.97M | ▲ 479.19K |
| Commodore Capital LP | 2.87M | ▼ 1.53M |
| Millennium Management LLC | 2.75M | ▼ 283.61K |
| Spruce Street Capital LP | 2.20M | 0 |
| Sessa Capital Im, L.P. | 2.20M | 0 |
Held by 72 ETFs
Biggest fund positions in SABS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 17, 26 | Kropotova Alexandra | other | 473 |
| Jun 25, 26 | Kropotova Alexandra | other | 988 |
| Mar 24, 26 | Kropotova Alexandra | other | 988 |
| Feb 3, 26 | Sullivan Eddie Joe | other | 3,000,000 |
| Feb 3, 26 | Reich Samuel J | other | 4,800,000 |
| Feb 3, 26 | Bausch Christoph Lawrence | other | 1,800,000 |
| Feb 3, 26 | Kropotova Alexandra | other | 2,400,000 |
| Feb 3, 26 | To Lucy | other | 2,400,000 |
| Jan 5, 26 | Jain Rita | other | 240,000 |
| Jan 5, 26 | ZACCARDELLI DAVID | other | 240,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SABS coverage
Recent articles, reports, and earnings notes.
No research on SABS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SABS report →SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress
globenewswire.com · Oct 1
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Stock Rated “Moderate Buy” by Sell-Side Analysts
defenseworld.net · Sep 30
SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes
globenewswire.com · Sep 22
SAB Biotherapeutics, Inc. (SABS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
seekingalpha.com · Sep 10
SAB BIO to Participate in Upcoming Investor Conferences
globenewswire.com · Sep 1
375,000 Shares in SAB Biotherapeutics, Inc. $SABS Purchased by AWM Investment Company Inc.
defenseworld.net · Aug 26
SAB Biotherapeutics Q2 Earnings Call Highlights
marketbeat.com · Aug 7
SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights
globenewswire.com · Aug 6
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.